Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

This study is ongoing, but not recruiting participants.

First Received: June 30, 2006 Last Updated: January 23, 2008 History of Changes

Sponsored by:	Asociación para Evitar la Ceguera en México
Information provided by:	Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:	NCT00599820

Purpose

Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

Condition	Intervention	Phase
Angioid Streaks Choroidal Neovascularization	Drug: Intravitreal Bevacizumab	Phase III

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title:	OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angioid Streaks Treated With a Single Intravitreal Injection of Bevacizumab

Resource links provided by NLM:

Drug Information available for: Bevacizumab

U.S. FDA Resources

Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:

BCVA
Fluoresceine Angiography
Optical Coherence Tomography

Study Start Date:	November 2005
Estimated Study Completion Date:	May 2006

Detailed Description:

A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Clinical diagnosis of Angioid Streaks
Choroidal neovascularization associated
Untreated patients or patients treated once with PDT

Exclusion Criteria:

Ocular surgery excepting uncomplicated phacoemulsification
Glaucoma or any other ocular pathology

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00599820

Locations

Mexico, Distrito Federal
Asociación para Evitar la Ceguera en México (APEC)
México city, Distrito Federal, Mexico, 04030

Sponsors and Collaborators

Asociación para Evitar la Ceguera en México

Investigators

Principal Investigator:	Adriana Solís-Vivanco, MD	Asociación para Evitar la Ceguera en México
Study Chair:	Jans Fromow-Guerra, MD PhD	Asociación para Evitar la Ceguera en México
Study Chair:	Mariana Martínez-Castellanos, MD	Asociación para Evitar la Ceguera en México
Study Chair:	Elizabeth Reyna-Castelán, MD	Asociación para Evitar la Ceguera en México
Study Chair:	Myriam Hernández-Rojas, MD	Asociación para Evitar la Ceguera en México
Study Chair:	Griselda Alvarez-Rivera, MD	Asociación para Evitar la Ceguera en México
Study Director:	Hugo Quiroz-Mercado, MD	Asociación para Evitar la Ceguera en México

More Information

No publications provided

Study ID Numbers:	APEC 010
Study First Received:	June 30, 2006
Last Updated:	January 23, 2008
ClinicalTrials.gov Identifier:	NCT00599820 History of Changes
Health Authority:	Mexico: National Institute of Public Health, Health Secretariat

Keywords provided by Asociación para Evitar la Ceguera en México:

Angioid Streaks
Choroidal Neovascularization
Bevacizumab

Study placed in the following topic categories:

Uveal Diseases
Metaplasia
Eye Diseases
Choroid Diseases
Neoplasm Metastasis
Bevacizumab

Neovascularization, Pathologic
Angiogenesis Inhibitors
Retinal Diseases
Angioid Streaks
Choroidal Neovascularization

Additional relevant MeSH terms:

Uveal Diseases
Antineoplastic Agents
Eye Diseases
Growth Substances
Physiological Effects of Drugs
Choroid Diseases
Bevacizumab
Angiogenesis Inhibitors
Pharmacologic Actions

Choroidal Neovascularization
Pathologic Processes
Therapeutic Uses
Metaplasia
Growth Inhibitors
Neovascularization, Pathologic
Angiogenesis Modulating Agents
Angioid Streaks
Retinal Diseases

ClinicalTrials.gov processed this record on September 03, 2009